Prior chemotherapy, targeted small molecule therapy, or radiation therapy within two weeks prior to registration for protocol therapy; Note: If the subjects have undergone major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting protocol therapy
Participants must have recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy
Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study allocation. (Notes: Participants must have recovered from all AEs due to previously administered therapies to ? Grade 1 or baseline. If a participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.)
SAFETY RUN-IN: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
RANDOMIZED PHASE II CLINICAL TRIAL: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the participant received major surgery or radiation therapy of >30 Gray units, they must have recovered from the toxicity and/or complications from the intervention
If subject underwent major surgery they must have recovered adequately from the toxicity and/or complications from the procedure prior to starting therapy
Participants who have not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy
If had major surgery, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to study registration
Patients must be adequately recovered from surgery, radiation therapy, or any surgical complications prior to enrollment
Surgery within 4 weeks prior to study registration except for minor procedures. NOTE: Hepatic biliary stent placement is allowed. NOTE: Subject must have adequately recovered from the toxicity and/or complications of major surgery prior to study registration, as determined by the treating physician.
Not recovered from AEs and/or complications from major surgery prior to first dose
Has received prior chemotherapy (including investigational agents) for any malignant disorder, thoracic radiation therapy or prior surgical resection of an esophagogastric tumor\r\n* Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
If received major surgery, not recovered adequately from the toxicity and/or complications from the intervention prior to starting the study
If subjects received major surgery they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting trial therapy
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention and at least two weeks have to pass prior to starting therapy
Have resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the patient received major surgery or radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
Major surgery within 28 days prior to start of study treatment and failure to have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study treatment.
Has had major surgery within 4 weeks or minor surgery within 2 weeks prior to study day 1; subjects must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention per clinical discretion of the investigator prior to starting therapy
Prior major surgery within 2 weeks prior to the first dose of study drug or who has not recovered adequately from the toxicity and/or complications from the intervention
Major surgery =< 28 days prior to registration; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has received locoregional therapy to liver (transarterial chemoembolization (TACE), transarterial embolization (TAE), radiation, radioembolization, or ablation) or surgery to liver or other site within 6 weeks prior to the first dose of study drug; minor surgery must have occurred at least 7 days prior to the first dose of study treatment (cycle 1, day 1); subjects must have recovered adequately (i.e., grade =< 1 or baseline) from the toxicity and/or complications from any intervention prior to starting therapy
Have resolution of toxic effect(s) of the most recent prior chemotherapy to grade 1 or less (except alopecia); if subject received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention
If subject underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
For subjectâ€™s who have received major surgery, the subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy
Has undergone major surgery within 3 weeks of Study Day 1, Subject must have recovered adequately from any toxicity and/or complications from the intervention prior to starting therapy;
Has not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy
REGISTRATION TO TREATMENT (STEP 1): Patients who have received major surgery must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
REGISTRATION TO TREATMENT (STEP 2): Patients who have received major surgery must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Received major surgery =< 2 weeks prior to registration, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who received major surgery must be recovered adequately from the toxicity and/or complications from the interventions prior to starting therapy
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment start\r\n* Note: participants must have recovered from all adverse events (AEs) due to previous therapies to =< grade 1 or baseline; participants with =< grade 2 neuropathy may be eligible\r\n* Note: if participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
Has not recovered adequately (i.e., Grade ?1 or baseline) from the toxicity and/or complications from any intervention prior to starting study drug.
Complete resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the subject received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
Has had prior radiation, chemotherapy, targeted therapy, or investigational therapy for cervical cancer\r\n* Note: if subject received major surgery for reason other than cervical cancer, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting treatment
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had major surgery or significant traumatic injury within 4 weeks of study registration. Subjects must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. A diagnostic or research biopsy does not exclude subjects from enrollment. Placement of a vascular access device such as a Port-A-Cath is not considered major surgery
Surgery within 4 weeks prior to study treatment except for minor procedures: NOTES: Hepatic biliary stent placement is allowed. Subject must have adequately recovered from the toxicity and/or complications of major surgery prior to study registration, as determined by the treating physician.
Patient is currently participating in or has participated in a study of an investigational systemic agent to treat MCC; or is using an investigational device within 4 weeks of the first dose of treatment\r\n* NOTE: if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Toxicity from surgery or associated interventions that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parameters
If the patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has undergone major surgery and has not recovered adequately from any toxicity and/or complications from the intervention prior to starting study therapy
Has had major surgery within 3 weeks prior to receiving the first dose of study treatment or has not recovered adequately from toxicity and/or complications from an intervention prior to receiving the first dose of study treatment.
If a subject received major surgery, must have recovered adequately from the toxicity and/or complications from the intervention prior to enrollment.
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior radiation therapy for metastatic melanoma is allowed as long as the patient bears measurable actively growing disease outside the previously irradiated field\r\n* NOTE: if subject received major surgery, they must have recovered adequately from the toxicity (i.e., all symptoms =< grade 1) and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1; Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
